Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Breast Cancer Outcomes by Enhanced Activities in Early Detection and Diagnosis: An Umbrella Review and Meta-Analyses of Randomised Controlled Trials in High-Income Contexts With Universal Healthcare Coverage.

Cancer control : journal of the Moffitt Cancer Center·2026
Same author

Evaluation of the Quality and Suitability of Self-Collected Vaginal and Urine Samples for Human Papillomavirus Testing: A Prospective Matched Study.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Interventions for patients with prostate cancer on active surveillance: a narrative review.

BJU international·2025
Same author

Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective.

British journal of cancer·2025
Same author

Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States.

Journal of the National Cancer Institute·2024
Same author

Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer.

JAMA·2024
Same journal

Erratum regarding missing Declaration of Competing Interest statements in previously published articles.

Papillomavirus research (Amsterdam, Netherlands)·2020
Same journal

Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques.

Papillomavirus research (Amsterdam, Netherlands)·2020
Same journal

Strong reduction in prevalence of HPV16/18 and closely related HPV types in sexually active adolescent women following the introduction of HPV vaccination in Argentina.

Papillomavirus research (Amsterdam, Netherlands)·2020
Same journal

No association between HPV-status in tonsillar tissue and sexual behavior of the patients in a northern German population - Critical view of the link between HPV natural history and HPV-driven carcinogenesis.

Papillomavirus research (Amsterdam, Netherlands)·2020
Same journal

CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings.

Papillomavirus research (Amsterdam, Netherlands)·2020
Same journal

Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants.

Papillomavirus research (Amsterdam, Netherlands)·2020
See all related articles

Related Experiment Video

Updated: Feb 20, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.3K

Need for expanded HPV genotyping for cervical screening.

Jack Cuzick1, Cosette Wheeler2

  • 1Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom.

Papillomavirus Research (Amsterdam, Netherlands)
|October 28, 2017
PubMed
Summary
This summary is machine-generated.

Human papillomavirus (HPV) genotyping for cervical cancer screening should consider types beyond 16 and 18. HPV31 and HPV33 show higher predictive value for high-grade lesions than HPV18.

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.3K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

13.0K

Related Experiment Videos

Last Updated: Feb 20, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.3K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.3K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

13.0K

Area of Science:

  • Oncology
  • Virology
  • Genetics

Background:

  • Cervical cancer screening traditionally focuses on HPV types 16 and 18 due to their high prevalence.
  • Screening aims to detect high-grade precursor lesions (CIN2/CIN3), where a broader range of HPV types are implicated.
  • Current HPV genotyping strategies may not fully capture the risk associated with all relevant HPV types.

Discussion:

  • HPV16 maintains high predictive value for high-grade cervical lesions.
  • HPV31 and HPV33 demonstrate superior positive predictive values (PPVs) compared to HPV18 in detecting CIN2/CIN3.
  • The PPVs of HPV types 39, 56, 59, and 68 are significantly lower than those of established high-risk types (e.g., 16, 18, 31, 33, 35, 45, 51, 52, 58).

Key Insights:

  • HPV genotyping for cervical cancer screening requires a nuanced approach beyond just HPV16 and HPV18.
  • HPV31 and HPV33 are critical high-risk types for identifying significant cervical abnormalities.
  • HPV types 39, 56, 59, and 68 are reclassified as 'intermediate risk' based on their lower PPVs.
  • HPV type 66 does not appear to confer an increased risk for high-grade cervical lesions.

Outlook:

  • Future cervical cancer screening protocols should incorporate a more comprehensive HPV genotyping panel.
  • Re-evaluation of HPV risk stratification is necessary to optimize screening and management strategies.
  • Further research may refine the classification of intermediate-risk HPV types and their clinical significance.